DOCSLIB.ORG

Lumicera Specialty Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lumicera Specialty Drug List Lumicera Specialty Drug List The Lumicera Specialty Drug list is a guide to medications distributed through Lumicera Specialty Pharmacy. Our mission is to provide exceptional service and comprehensive care so that our members can live happier, better lives. In fact, our dedication has earned us a 99% patient satisfaction rate. We support our prescribers and members with pre-screening therapy, ongoing support and education, clinical monitoring and refill reminders. Condition Brand Name Generic Name Allergy/Asthma, Dermatology, Actemra® tocilizumab Gastroenterology, Rheumatology, Avsola® infliximab - axxq Benlysta® belimumab Cimzia® certolizumab Cosentyx® secukinumab Dupixent® dupilumab Enbrel® etanercept Entyvio® vedolizumab Fasenra®* benralizumab Humira® adalimumab Ilumya® tildrakizumab-asmn Inflectra® infliximab-dyyb Kevzara® sarilumab Nucala® mepolizumab Olumiant® baricitinib Orencia® abatacept Otezla® apremilast Otrexup® methotrexate Rasuvo® methotrexate Remicade® infliximab Renflexis® infliximab-abda *Health Sytem Own Use **Support medications only dispensed with other specialty medications Access Limitations May Apply 1 © 2021 Lumicera Health Services, LLC. All rights reserved. Condition Brand Name Generic Name Allergy/Asthma, Dermatology, Rinvoq® upadacitinib Gastroenterology, Rheumatology, Siliq® brodalumab Simponi/Simponi Aria® golimumab Skyrizi® risankizumab Soriatane® acitretin Stelara® ustekinumab Talt z ® ixekizumab Tremfya® guselkumab Xeljanz/Xeljanz XR® tofacitinib Xolair® omalizumab Condition Brand Name Generic Name Cystic Fibrosis Cayston® aztreonam Pulmozyme® dornase alfa Tobi/Tobi Podhaler® tobramycin *Health Sytem Own Use **Support medications only dispensed with other specialty medications Access Limitations May Apply 2 © 2021 Lumicera Health Services, LLC. All rights reserved. Condition Brand Name Generic Name Growth Hormone Genotropin® somatropin Humatrope® somatropin Norditropin® somatropin Nutropin AQ NuSpin® somatropin Omnitrope® somatropin Saizen® somatropin Zomacton® somatropin Zorbtive® somatropin Condition Brand Name Generic Name Hepatitis C Epclusa® velpatasvir/sofosbuvir Harvoni® ledipasvir/sofosbuvir Mavyret® glecaprevir/pibrentasvir Rebetol® ribavirin dasabuvir/ombitasvir/ Viekira Pak® paritaprevir/ritonavir Sofosbuvir/velpatasvir, Vosevi® voxilaprevir Zepatier® elbasvir/grazoprevir *Health Sytem Own Use **Support medications only dispensed with other specialty medications Access Limitations May Apply 3 © 2021 Lumicera Health Services, LLC. All rights reserved. Condition Brand Name Generic Name Hematology/Oncology Aranesp®** darbapoetin alfa Supplemental Rx Arimidex®** anastrozole Aromasin®** Exemestane Epogen®** epoetin alfa Exjade® deferasirox Femara® letrozole Fulphila® pegfilgrastim-jmdb Granix® tbo-filgrastim Hydrea®** hydroxyurea Jadenu® deferasirox Mesnex® mesna Mozobil® plerixafor Neulasta® pegfilgrastim Neupogen® filgrastim Nivestym® filgrastim-aafi Nolvadex®** tamoxifen Nplate® romiplostim Procrit®** epoetin alfa Promacta® eltrombopag olamine Retacrit® epoetin alfa-epbx Sandostatin/LAR® octreotide Udenyca® pegfilgrastim-cbqv Xgeva® denosumab Zarxio® filgrastim-sndz Ziextenzo® pegfilgrastim-bmez Zirabvex® bevacizumab-bvzr *Health Sytem Own Use **Support medications only dispensed with other specialty medications Access Limitations May Apply 4 © 2021 Lumicera Health Services, LLC. All rights reserved. Condition Brand Name Generic Name Multiple Sclerosis Aubagio® teriflunomide Avonex® interferon B-1a Betaseron® interferon B-1b Copaxone® glatiramer acetate Ampyra® dalfampridine Extavia® interferon B-1b Gilenya® fingolimod Glatopa® glatiramer acetate Kesimpta® ofatumumab Mayzent® siponimod Plegridy® peginterferon B-1a Rebif® iInterferon B-1a Tecfidera® dimethyl fumarate Vumerity® diroximel fumarate Zeposia® ozanimod Condition Brand Name Generic Name Oncology/Hematology Afinitor® Everolimus Alecensa®* alectinib Alunbrig®* brigatinib Ayvakit®* avapritinib Balversa® erdafitinib Bosulif®* bosutinib Braftovi®* encorafenib Brukinsa®* zanubrutinib Cabometyx®* cabozantinib *Health Sytem Own Use **Support medications only dispensed with other specialty medications Access Limitations May Apply 5 © 2021 Lumicera Health Services, LLC. All rights reserved. Condition Brand Name Generic Name Oncology/Hematology Calquence®* acalabrutinib Copiktra®* duvelisib Cotellic®* cobimetinib Cytoxan® cyclophosphamide Daurismo®* glasdegib Doptelet®* avatrombopag Eligard® leuprolide Erivedge®* vismodegib Erleada*® apalutamide Fulphila® pegfilgrastim-jmdb Giotrif®* afatinib Gleevec® imatinib Gleostine® lomustine Herzuma® trastuzumab-pkrb Hycamtin® topotecan Ibrance®* palbociclib Imbruvica®* ibrutinib Inlyta®* axitinib Inqovi®* decitabine/cedazuridine Inrebic® fedratinib Iressa®* gefitinib Jakafi®* ruxolitinib Kanjinti® trastuzumab-anns Kisqali® ribociclib Koselugo®* selumetinib Lenvima®* lenvatinib Leukeran® Chlorambucil *Health Sytem Own Use **Support medications only dispensed with other specialty medications Access Limitations May Apply 6 © 2021 Lumicera Health Services, LLC. All rights reserved. Condition Brand Name Generic Name Oncology/Hematology Lonsurf®* trifluridine/tipiracil Lorbrena®* lorlatinib Lupron® leuprolide acetate Lynparza®* olaparib Mekinist® trametinib Mozobil® plerixafor Mvasi® bevacizumab-awwb Nerlynx®* neratinib Neulasta® Pegfilgrastim Nexavar®* sorafenib Nilandron® nilutamide Ninlaro®* ixazomib Nplate® romiplostim Nubeqa®* darolutamide Odomzo® sonidegib Ogivri® trastuzumab-dkst Ontruzant® trastuzumab-dttb Onureg® azacitadine Pegasys® Peginterferon A-2a PEGIntron Redipen® Peginterferon A-2b Piqray® alpelisib Promacta® eltrombopag Olamine Retevmo®* selpercatinib Rozlytrek®* entrectinib Rubraca®* rucaparib Rydapt® midostaurin *Health Sytem Own Use **Support medications only dispensed with other specialty medications Access Limitations May Apply 7 © 2021 Lumicera Health Services, LLC. All rights reserved. Condition Brand Name Generic Name Oncology/Hematology Somatuline Depot® lanreotide Sprycel® dasatinib Stivarga®* regorafenib Sutent®* sunitinib Tabrecta® capmatinib Tafinlar® Dabrafenib Tagrisso®* osimertinib Talzenna®* talazoparib Tarceva® erlotinib Targretin® Bexarotene Targretin Gel® Bexarotene Tasigna® nilotinib Tazverik®* tazemetostat Temodar® Temozolomide Thyrogen® thyrotropin Alfa Tibsovo®* ivosidenib Trazimera® trastuzumab-qyyp Truxima® rituximab-abbs Tukysa®* tucatinib Tykerb® Lapatinib Venclexta®* venetoclax Vepesid® etoposide Verzenio®* abemaciclib Vesanoid® tretinoin (oral) Vitrakvi®* larotrectinib Votrient® Pazopanib *Health Sytem Own Use **Support medications only dispensed with other specialty medications Access Limitations May Apply 8 © 2021 Lumicera Health Services, LLC. All rights reserved. Condition Brand Name Generic Name Oncology/Hematology Xalkori®* crizotinib Xeloda® Capecitabine Xgeva® Denosumab Xospata®* gilteritinib Xtandi®* enzalutamide Yonsa® abiraterone Zejula®* niraparib Zelboraf®* vemurafenib Zirabvex® bevacizumab-bvzr Zolinza® vorinostat Zometa® zoledronic Acid Zydelig®* idelalisib Zykadia® ceritinib Zytiga®* abiraterone acetate Condition Brand Name Generic Name Osteoporosis Evenity® romosozumab Forteo® teriparatide Prolia® denosumab Reclast® zoledronic Acid Tymlos® abaloparatide *Health Sytem Own Use **Support medications only dispensed with other specialty medications Access Limitations May Apply 9 © 2021 Lumicera Health Services, LLC. All rights reserved. Condition Brand Name Generic Name Other Abilify Maintena® aripiprazole Adcirca® tadalafil Letairis® ambrisentan Aristada® aripiprazole lauroxil Austedo® deutetrabenazine Beovu® brodlucizumab-dbll Botox® onabotulinumtoxin A Cuprimine® penicillamine Depen® penicillamine Dibenzyline® phenoxybenzamine Durolane® hyaluronic acid Dysport® abobotulinmutoxin A Endari® glutamine Enspryng®* satralizumab Epidiolex® cannabidiol Esbriet® pirfenidone Euflexxa® hyaluronate sodium Firazyr® icatibant acetate Gel-One® hyaluronate sodium *Health Sytem Own Use **Support medications only dispensed with other specialty medications Access Limitations May Apply 10 © 2021 Lumicera Health Services, LLC. All rights reserved. Condition Brand Name Generic Name Other GelSyn-3® hyaluronate sodium GenVisc 850® hyaluronate sodium Hemlibra® emicizumab Hyalgan® hyaluronate sodium Hymovis® hyaluronan Ingrezza®* valbenazine Invega Sustenna® paliperidone palmitate Krystexxa®* pegloticase Leukine® sargramostim leuprolide acetate and Lupaneta® norethindrone acetate Makena® hydroxyprogesterone caproate Monovisc® hyaluronic acid Orthovisc® hyaluronic acid Relistor® methylnaltrexone bromide Supartz FX® hyaluronic acid Synagis® palivizumab Synvisc/Synvisc One® hylan polymers A and B Syprine® trientine hydrochloride Visco-3® hyaluronic acid Vivitrol® naltrexone Vyndaqel®* tafamidis meglumine Xenazine® tetrabenazine Zortress® everolimus *Health Sytem Own Use **Support medications only dispensed with other specialty medications Access Limitations May Apply 11 © 2021 Lumicera Health Services, LLC. All rights reserved..
Load more

Recommended publications
  • Quarterly Review
    Tropical Gastroenterology 2008.29;4:187–193 Quarterly Have hematopoietic growth factors made an Review impact on the management of liver disease? Pankaj Tyagi and Kaushal Madan ABSTRACT Department of Gastroenterology, It is clear that the major indication for the use of hematopoietic growth factors in hepatology GB Pant Hospital & Department of is to counteract the adverse effects of interferons (neutropenia and thrombocytopenia) and Medical Hepatology, ribavirin (hemolytic anaemia) during the treatment of hepatitis C infection. This is important Institute of Liver and Biliary Sciences, because the probability of SVR depends on proper adherence to therapy (at least 80% of the New Delhi requisite dose maintained for at least 80% of the requisite duration) and proper adherence can only be achieved if the side effects are reduced to a minimum. Even though the studies Correspondence: Dr. Kaushal Madan have demonstrated beyond doubt that the use of hematopoietic growth factors does indeed Email: [email protected] reduce the incidence and severity of these adverse effects and helps the patients to complete the course of therapy, the data on improvement of SVR is still limited. There is only one study of darbepoetin and filgrastim showing the beneficial effect on SVR. Even among the hematological side effects, possibly the only significant effect which limits the use of optimal HCV therapy is the hemolytic anaemia induced by ribavirin. The other two main side effects, i.e. neutropenia and thrombocytopenia are not clinically problematic. The use of such growth factors would be particularly effective if patients who have advanced liver disease or cirrhosis are able to receive adequate anti-viral therapy as has been demonstrated in the study of eltrombopag among HCV cirrhotics.
    [Show full text]
  • STIM1 Controls Calcineurin/Akt/Mtor/NFATC2‑Mediated Osteoclastogenesis Induced by RANKL/M‑CSF
    736 EXPERIMENTAL AND THERAPEUTIC MEDICINE 20: 736-747, 2020 STIM1 controls calcineurin/Akt/mTOR/NFATC2‑mediated osteoclastogenesis induced by RANKL/M‑CSF YANJIAO HUANG1, QIANG LI2, ZUNYONG FENG3 and LANRONG ZHENG1 Departments of 1Pathological Anatomy, 2Anatomy and 3Forensic Medicine, Wannan Medical College, Wuhu, Anhui 241002, P.R. China Received October 15, 2018; Accepted June 20, 2019 DOI: 10.3892/etm.2020.8774 Abstract. Store-operated Ca2+ entry (SOCE) is the stable (p.E136X, p.R429C) or constitutively activated (p.R304W) calcium channel influx in most cells. It consists of the SOCE, failed to respond to RANKL/M-CSF-mediated induc- cytoplasmic ion channel ORAI and endoplasmic reticulum tion of normal osteoclastogenesis. In addition, activation of the receptor stromal interaction molecule 1 (STIM1). Abolition calcineurin/Akt/mTOR/NFATC2 signalling cascade induced of SOCE function due to ORAI1 and STIM1 gene defects by RANKL/M-CSF was abnormal in the BMDMs with may cause non-perspiration, ectoderm dysplasia and STIM1 mutants compared with that in BMDMs from healthy skeletal malformations with severe combined immunodefi- subjects. In addition, overexpression of wild-type STIM1 ciency (CID). Calcineurin/mammalian target of rapamycin restored SOCE in p.R429C- and p.E136X-mutant BMDMs, but (mTOR)/nuclear factor of activated T cells 2 (NFATC2) is not in p.R304W-mutant BMDMs. Of note, calcineurin, cyclo- an important signalling cascade for osteoclast development. sporin A, mTOR inhibitor rapamycin and NFATC2‑specific Calcineurin is activated by Ca2+ via SOCE during osteoclas- small interfering RNA restored the function of SOCE in togenesis, which is induced by receptor activator of NF-κB p.R304W-mutant BMDMs.
    [Show full text]
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • Therapeutic Class Overview Colony Stimulating Factors
    Therapeutic Class Overview Colony Stimulating Factors Therapeutic Class Overview/Summary: This review will focus on the granulocyte colony stimulating factors (G-CSFs) and granulocyte- macrophage colony stimulating factors (GM-CSFs).1-5 Colony-stimulating factors (CSFs) fall under the naturally occurring glycoprotein cytokines, one of the main groups of immunomodulators.6 In general, these proteins are vital to the proliferation and differentiation of hematopoietic progenitor cells.6-8 The G- CSFs commercially available in the United States include pegfilgrastim (Neulasta®), filgrastim (Neupogen®), filgrastim-sndz (Zarxio®), and tbo-filgrastim (Granix®). While filgrastim-sndz and tbo- filgrastim are the same recombinant human G-CSF as filgrastim, only filgrastim-sndz is considered a biosimilar drug as it was approved through the biosimilar pathway. At the time tbo-filgrastim was approved, a regulatory pathway for biosimilar drugs had not yet been established in the United States and tbo-filgrastim was filed under its own Biologic License Application.9 Only one GM-CSF is currently available, sargramostim (Leukine). These agents are Food and Drug Administration (FDA)-approved for a variety of conditions relating to neutropenia or for the collection of hematopoietic progenitor cells for collection by leukapheresis.1-5 Due to the pathway taken, tbo-filgrastim does not share all of the same indications as filgrastim and these two products are not interchangeable. It is important to note that although filgrastim-sndz is a biosimilar product, and it was approved with all the same indications as filgrastim at the time, filgrastim has since received FDA-approval for an additional indication that filgrastim-sndz does not have, to increase survival in patients with acute exposure to myelosuppressive doses of radiation.1-3A complete list of indications for each agent can be found in Table 1.
    [Show full text]
  • September 11, 2018 DUR Minutes
    Maine Department of Health and Human Services PAUL R. LEPAGE MaineCare Services BETHANY L. HAMM GOVERNOR Pharmacy Unit ACTING COMMISSIONER 11 State House Station Augusta, Maine 04333-0011 TO: Maine Drug Utilization Review Board DATE: 9/14/2018 RE: Maine DUR Board Meeting minutes from September 11, 2018 ATTENDANCE PRESENT ABSENT EXCUSED Linda Glass, MD X Lisa Wendler, Pharm. D., Clinical Pharmacy Specialist, X Maine Medical CTR Mike Antoniello, MD X Kathleen Polonchek, MD X Kenneth McCall, PharmD X Steve Diaz, MD X Erin Ackley, PharmD. X Corinn Martineau, PharmD. X Non –Voting Mike Ouellette, R.Ph., Change Healthcare X Jeffery Barkin, MD, Change Healthcare X Christopher Pezzullo, State Health Officer DHHS, DO X Jill Kingsbury, MaineCare Pharmacy Director X Guests of the Board: Ed Bosshart, PharmD, Jeff Caulfield, Lead Epidemiologist for Viral Infections from CDC: Discussed HCV treatment. CALL TO ORDER: 5:30PM Jill Kingsbury called the meeting to order at 5:30 PM. PUBLIC COMMENTS Robert Mead from Pfizer: Highlighted the attributes of Retacrit. Jane Guo from Otsuka: Highlighted the attributes of Jynarque. OLD BUSINESS DUR MINUTES The June DUR meeting minutes were accepted as written. MAINECARE UPDATE No update at this time. NEW BUSINESS INTRODUCTION: USE OF CHRONIC TRIPTANS The use of triptans has become standard of care for the treatment of acute migraine headaches, given their effectiveness, safety and tolerability. However, like many medications used to treat migraine, overuse renders them less effective. Additionally, rebound headaches from triptan overuse is common. For patients who experience frequent headaches, or whose headaches are long lasting or chronic, use of headache prophylactic medications are recommended by several medical associations, including the American Headache Society and the American Academy of Neurology.
    [Show full text]
  • Managing Adverse Effects and Complications in Completing Treatment for Hepatitis C Virus Infection
    HCV Treatment Complications Volume 20 Issue 4 October/November 2012 Perspective Managing Adverse Effects and Complications in Completing Treatment for Hepatitis C Virus Infection The addition of direct-acting antivirals (DAAs) to hepatitis C virus (HCV) Psychiatric Complications treatment regimens has made treatment more effective and patient Depression is the most common psy- management more complex. Shepherding patients through a full course of chiatric complication encountered in HCV therapy requires motivation and involvement on the part of the patient HCV patients, with mild to moderate and the physician. Indeed, physician inexperience and lack of confidence in depression found in as much as 80% of guiding patients through the challenges of treatment appears to be a primary patients. Bipolar disorder and schizo- reason for early discontinuation of therapy. Among the many complications phrenia are also not infrequently en- of HCV treatment that must be managed efficiently and effectively are countered. depression and other psychiatric disorders; hematologic abnormalities There is little evidence to support including DAA- and ribavirin-associated anemia and peginterferon alfa- a benefit of preemptive antidepres- associated neutropenia and thrombocytopenia; rash and drug eruptions, sant therapy in all patients undergo- including telaprevir-associated rash; and weight loss. Practical considerations ing HCV treatment, though a recent in management of these common complications are offered. This article randomized trial of HCV patients
    [Show full text]
  • FULPHILA Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULPHILA safely and effectively. See full prescribing information for -----------------------WARNINGS AND PRECAUTIONS----------------------­ FULPHILA. • Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. (5.1) ™ FULPHILA (pegfilgrastim-jmdb) injection, for subcutaneous use • Acute respiratory distress syndrome (ARDS): Evaluate patients who Initial U.S. Approval: 2018 develop fever, lung infiltrates, or respiratory distress. Discontinue ™ ® Fulphila in patients with ARDS. (5.2) FULPHILA (pegfilgrastim-jmdb) is biosimilar* to NEULASTA • Serious allergic reactions, including anaphylaxis: Permanently (pegfilgrastim). (1) discontinue Fulphila in patients with serious allergic reactions. (5.3) • Fatal sickle cell crises: Have occurred. (5.4) ----------------------------INDICATIONS AND USAGE--------------------------- • Glomerulonephritis: Evaluate and consider dose-reduction or Fulphila is a leukocyte growth factor indicated to interruption of Fulphila if causality is likely. (5.5) • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving ------------------------------ADVERSE REACTIONS------------------------------ myelosuppressive anti-cancer drugs associated with a clinically Most common adverse reactions (≥ 5% difference in incidence compared to significant incidence of febrile neutropenia.
    [Show full text]
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • Treatment of MDS in 2014 and Beyond Treatment Goals in MDS
    5/22/2014 Treatment of MDS in 2014 and Beyond Treatment goals in MDS • Get rid of it May 17, 2014 • If you can’t do that, make life better and longer – Improve blood counts Gail J. Roboz, M.D. – Improve quality of life Director, Leukemia Program – Decrease time to progression/leukemia Associate Professor of Medicine Hematopoietic Growth Factors: Hematopoietic Growth Factors: What are they? What are they? • Erythropoietin (EPO,Procrit®, Epogen®) – red • Synthetic versions of proteins normally • Granulocyte colony stimulating factor (GCSF, made in the body to stimulate growth of red Neupogen®) – white cells, white cells and platelets • Granulocyte-macrophage colony stimulating • Promote growth and differentiation factor (GM-CSF, Leukine®) – white • Thrombopoietin (TPO, romiplostim, Nplate®) – • Inhibitors of apoptosis (cell death) platelets • Darbepoietin (Aranesp®) • Peg-filgrastim (Neulasta®) • Note, these are not FDA-approved for MDS Erythropoietin (epo) in MDS Erythropoietin (epo) in MDS • Anemia is presents in >80% of MDS pts at dx • Often high endogenous epo levels • Transfusions help, but many issues • Many different doses and schedules • Recombinant EPO is FDA-approved for treating • Higher response rates with epo + G-CSF if anemia associated with kidney failure epo ≤500 mU/mL and transfusions <2 • Has been used since about 1990 in MDS U/month • Response rates in about 15-30% of patients • Poor probability of response if epo >500 • Many different studies including >1000 patients mU/mL and transfusions >2 U/month • Part of the NCCN MDS treatment guidelines 1. Casadevall N, et al. Blood. 2004;104:321-327. 2. Hellstrom-Lindberg E. Br J Haematol. 1995;89:67-71.
    [Show full text]
  • Denosumab and Anti-Angiogenetic Drug-Related Osteonecrosis of the Jaw: an Uncommon but Potentially Severe Disease
    ANTICANCER RESEARCH 33: 1793-1798 (2013) Denosumab and Anti-angiogenetic Drug-related Osteonecrosis of the Jaw: An Uncommon but Potentially Severe Disease STEFANO SIVOLELLA1, FRANCO LUMACHI2, EDOARDO STELLINI1 and LORENZO FAVERO1 Departments of 1Neurosciences, Section of Dentistry and 2Surgery, Oncology and Gastroenterology, University of Padua, School of Medicine, Padova, Italy Abstract. Osteonecrosis of the jaw (ONJ) is a rare but bone exposure in the oral cavity (1). Experimental radio-ONJ serious lesion of the jaw characterized by exposed necrotic was first reported in the 1960s and better-described by Zach bone and is related to several drugs usually used for treating et al. (2, 3). Currently, ONJ may represent a serious problem patients with advanced malignancies. Common therapies in patients irradiated for head and neck carcinomas, but may inducing ONJ are nitrogen-containing bisphosphonates (BPs), also be an uncommon complication of cancer chemotherapy the human monoclonal antibody to the receptor activator of (4, 5). Other causes of ONJ are local malignancy, periodontal nuclear factor-kappa B ligand denosumab and some anti- disease, trauma, and long-term glucocorticoid or angiogenic drugs, alone or in combination with BPs. The real bisphosphonate (BP) therapy (6). ONJ is a potentially incidence of ONJ is unknown. Several cases of ONJ in patients debilitating disease, which occurs in approximately 5% of with cancer who underwent denosumab therapy have been patients with myeloma or bone metastases from breast cancer reported and it seems that the overall incidence of denosumab- (BC) or prostate cancer receiving high-dose intravenous BPs related ONJ is similar to that for BP-related in this (7).
    [Show full text]
  • Neuromyelitis Optica Spectrum Disorder
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-2596 Drug Class Review with New Drug Evaluation: Biologics for Autoimmune Disorders-Neuromyelitis Optica Spectrum Disorder Date of Review: April 2021 Date of Last Review: n/a Dates of Literature Search: 1/1/1996 – 1/20/2021 Generic Name: Brand Name (Manufacturer): Eculizumab Soliris® (Alexion Pharmaceuticals) Inebilizumab-cdon Uplizna™ (Viela Bio) Satralizumab-mwge Enspryng™ (Genentech/Roche) Dossiers Received: Yes Current Status of PDL Class: See Appendix 1. Purpose for Class Update: To define place in therapy for 3 immunosuppressive agents, eculizumab, inebilizumab-cdon, and satralizumab-mwge, recently approved by the Food and Drug Administration (FDA) for the treatment adults with neuromyelitis optica spectrum disorder (NMOSD). Research Questions: 1. What is the effectiveness of eculizumab, inebilizumab, and satralizumab in reducing time to relapse in adult patients with NMOSD who are anti-aquaporin-4 (AQP4) antibody positive? 2. What are the harms of eculizumab, inebilizumab-cdon and satralizumab in adults with NMOSD? 3. Is there comparative evidence that eculizumab, inebilizumab, and satralizumab differ in efficacy or harms for management of NMOSD? 4. Are there certain sub-populations (based on age, gender, ethnicity, comorbidities, disease duration or severity) in which eculizumab, inebilizumab, or satralizumab may be beneficial
    [Show full text]
  • Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: an Overview
    Journal of Clinical Medicine Review Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview Yoshiya Tanaka The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1, Iseigaoka, Kitakyushu 807-8555, Japan; [email protected]; Tel.: +81-93-603-1611; Fax: +81-93-691-7580 Abstract: In rheumatoid arthritis, a representative systemic autoimmune disease, immune abnor- mality and accompanying persistent synovitis cause bone and cartilage destruction and systemic osteoporosis. Biologics targeting tumor necrosis factor, which plays a central role in the inflammatory process, and Janus kinase inhibitors have been introduced in the treatment of rheumatoid arthritis, making clinical remission a realistic treatment goal. These drugs can prevent structural damage to bone and cartilage. In addition, osteoporosis, caused by factors such as menopause, aging, immobility, and glucocorticoid use, can be treated with bisphosphonates and the anti-receptor activator of the nuclear factor-κB ligand antibody. An imbalance in the immune system in rheumatoid arthritis induces an imbalance in bone metabolism. However, osteoporosis and bone and cartilage destruction occur through totally different mechanisms. Understanding the mechanisms underlying osteo- porosis and joint destruction in rheumatoid arthritis leads to improved care and the development of new treatments. Keywords: rheumatoid arthritis; osteoporosis; joint destruction; DMARD; biologics Citation: Tanaka, Y. Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview. J. Clin. Med. 2021, 10, 1. Introduction 1241. https://doi.org/10.3390/ Rheumatoid arthritis is a systemic autoimmune disease characterized by inflammatory jcm10061241 polyarthritis. It occurs commonly in women in their 30s to 60s, and often causes organ disorders.
    [Show full text]